The American Journal of Managed Care > April 2008
The American Journal of Managed Care - April 2008
April 15, 2008 – Scott V. Monte, PharmD; Nicole M. Paolini, PharmD; Erin M. Slazak, PharmD; Jerome J. Schentag, PharmD; and Joseph A. Paladino, PharmD
Compared with other costs of treatment, expenditures for antibiotics were nominal in an adult primary care population with lower respiratory tract infections.
April 15, 2008 – Peter J. Neumann, ScD; Jennifer A. Palmer, MS; Norman Daniels, PhD; Karen Quigley, MPH; Marthe R. Gold, MD; and Schumarry Chao, MD, MBA, for the Panel on Integrating Cost-Effectiveness Considerations
A panel composed of medical and pharmacy directors expressed strong support for a greater role for cost-effectiveness analysis in US health policy decisions.
April 15, 2008 – Michael Schatz, MD; Robert S. Zeiger, MD, PhD; David Mosen, PhD; and William M. Vollmer, PhD
Asthma-specific quality of life and a history of acute episodes can be used together to identify risks of subsequent acute exacerbations.
April 15, 2008 – Nadereh Pourat, PhD; Guoyu A. Tao, PhD; and Cathleen M.Walsh, DrPh
Among young, sexually active women, self-reported Chlamydia trachomatis screening rates were primarily influenced by risk factors rather than insurance coverage.
Improved Health-related Quality of Life With Effective Disease-modifying Antirheumatic Drugs: Evidence From Randomized Controlled Trials
April 15, 2008 – Vibeke Strand, MD; Jasvinder A. singh, MD, MPH
Does Sharing Care Across the Primary–Specialty Interface Improve Outcomes in Chronic Disease? A Systematic Review
April 15, 2008 – Susan M. Smith, MD; Shane Allwright, PhD; and Tom O'Dowd, MD
Evidence to support the introduction of shared care services into clinical practice is limited, although methodologic shortcomings may account for this lack of evidence.
The American Journal of Managed Care
TRENDS FROM THE FIELD
April 15, 2008 – Paul C. Nagle, BSBA; Christopher A. Nicita, MBA; Leslie A. Gerdes, BA; and Cynthia J. Schmeichel, PhD
Research on characteristics of the biopharmaceutical pipeline and on changes since 2003 includes a description of new features and recommendations for health policy decision makers.